BeiGene Shares Are Trading Higher After the Company Announced FDA Approval of Tevimbra/chemotherapy Combination.
B of A Securities Downgrades Zai Lab to Neutral, Raises Price Target to $36.1
Zai Lab Analyst Ratings
Earnings Call Summary | Zai Lab(ZLAB.US) Q4 2024 Earnings Conference
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript Summary
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results.